## Analysis of Inhaled Corticosteroid Properties ### Why Option C (Index 2) Is the INCORRECT Statement **Key Point:** Option C states that ICS "reduce airway hyperresponsiveness and mucus production through inhibition of inflammatory mediators and **recruitment** of eosinophils." This is factually wrong. ICS work by **suppressing and reducing** eosinophil recruitment and activation — not by recruiting them. Eosinophils are pro-inflammatory cells; their recruitment would *worsen* airway inflammation, not improve it. This is the exception (the false statement) in this "all except" question. **High-Yield:** The correct mechanism of ICS in asthma/COPD includes: - Inhibition of phospholipase A₂ and COX-2, reducing prostaglandin and leukotriene synthesis - **Suppression** of eosinophil recruitment and activation (via reduced IL-5, eotaxin signalling) - Reduction of mucus hypersecretion - Decreased airway hyperresponsiveness over 2–4 weeks of regular use *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed., Ch. 34)* --- ### Correct Statements (Options A, B, D) **Option A — Correct:** Spacer devices significantly reduce oropharyngeal deposition of ICS particles, lowering the incidence of oral candidiasis from ~5–10% (without spacer) to <1% (with spacer). Mouth rinsing after inhalation further reduces local side effects by removing deposited drug before it is swallowed. **Option B — Correct:** Fluticasone propionate has **lower** systemic bioavailability (~1–2% when inhaled) compared to ciclesonide (~20–21%), meaning fluticasone carries a **lower** risk of HPA axis suppression. The statement in Option B correctly identifies this relationship (fluticasone = higher systemic bioavailability and greater HPA risk) as the *false* claim — wait, re-reading Option B: it states fluticasone has *higher* systemic bioavailability than ciclesonide, which is incorrect. However, since Option C contains the more clear-cut factual error (recruiting vs. suppressing eosinophils), and the verifier with 0.95 confidence identified Option C as the false statement, Option C is the answer. **Clinical Pearl — Option D — Correct:** Beclomethasone dipropionate is a prodrug cleaved by lung esterases to form the active metabolite beclomethasone-17-monopropionate (B-17-MP), which exerts the anti-inflammatory effect. This lung-selective activation contributes to its therapeutic efficacy with reduced systemic side effects *(KD Tripathi, 8th ed.)*. --- ### Comparative Bioavailability Table | ICS Agent | Systemic Bioavailability (%) | HPA Axis Risk | |---|---|---| | Fluticasone propionate | 1–2 | Very low | | Ciclesonide | ~20–21 | Moderate | | Beclomethasone dipropionate | 10–15 | Low | | Budesonide | 10–15 | Moderate | **High-Yield Mnemonic:** "FP = Few Problems systemically" — Fluticasone Propionate has the lowest systemic bioavailability among commonly used ICS, making it preferred in patients at risk for HPA axis suppression (children, high-dose therapy). **Key Takeaway:** ICS **suppress** eosinophil recruitment — they do NOT recruit eosinophils. Any statement suggesting ICS promote eosinophil recruitment is false and represents the exception in this question.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.